VAERS Explorer
Back to explore

Report #2877440

Received Dec 11, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Female
Age
19 yrs
State
DE
Recovered
Unknown
Vaccinated
Dec 8, 2025
Onset
Dec 8, 2025
Days to onset
0
Hospital days
—

Vaccines (1)

TypeNameManufacturerDoseLotRoute / Site
YFYELLOW FEVER (YF-VAX)SANOFI PASTEURUNKUK134AAOT / RA

Symptoms (2)

Expired product administeredNo adverse event

Symptom narrative

expired dose of YF-VAX was administered to a patient with no reported adverse event; Initial information received on 08-Dec-2025 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 19 years old female patient who was administered with a expired dose of Yellow Fever Vaccine- [YF-VAX] The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 08-Dec-2025, the patient received a 0.5 ml (1x) dose of suspect Yellow Fever Vaccine- solution for injection (strength: unknown) ( lot: UK134AA, expiry date: 30-Nov-2025) via intramuscular route in the right arm for immunization (expired product administered) (latency: same day). No adverse event was reported. It was reported "dose of YF-VAX was expired not the diluent. Patient's mother is concerned about revaccinating the same day since the dose only expired a little over a week ago. The patient's parent is concerned about patient's well-being in receiving an additional dose." Action taken: not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.